Cost-effectiveness analysis of eight first-line treatments for metastatic hormone-sensitive prostate cancer in China.

ABSTRACT:

Background

The treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has shifted from androgen deprivation therapy (ADT) alone to doublet or triplet regimens building on ADT. However, the cost-effectiveness analysis of first-line treatments for mHSPC in China is uncertain. This study aims to perform a 10-year horizon health economic evaluation to comparatively analyze the cost-effectiveness of eight treatment regimens for mHSPC from the perspective of China's healthcare system, including (1) ADT alone and ADT plus one of the following: (2) docetaxel, (3) abiraterone, (4) apalutamide, (5) enzalutamide, (6) rezvilutamide, (7) darolutamide and docetaxel, (8) abiraterone and docetaxel.

Methods

Partitioned survival model was developed to evaluate the cost-effectivenes

SUBMITTER: Han Z 

PROVIDER: S-EPMC12698425 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature